Resolute DES (Medtronic) delivers clinical benefits out to two years

The Resolute drug-eluting stent (DES), from Medtronic, maintains a powerful and persistent treatment effect for a wide variety of patients with Coronary Artery Disease, including those with Diabetes. A new study that includes 2 years of follow-up, the RESOLUTE US clinical study and two pooled analyses of the entire Resolute clinical program �� one on safety measures for all patients (RESOLUTE Pooled Safety), the other for all patients with diabetes (RESOLUTE Pooled Diabetes) -- reveals low rates of target lesion failure (TLF), target lesion revascularization (TLR) and definite/probable stent thrombosis (def/prob ST). In total, the program enrolled 5,130 patients who received a Resolute DES; about one third of which had Diabetes. Results show very low rates of clinically-driven TLR (4.7%) and def/prob ST (0.9%), despite 46 percent of the patients in the RESOLUTE program being considered complex, as well as consistently low event rates out to two years despite the higher-risk nature of the Diabetes patient population. Results were presented at the 61st Annual Scientific Session & Expo of the American College of Cardiology.